A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

相似書籍

• A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
  由: Paolo Strati, et al.
  出版: (2020-01-01)
• Efficacy of ifosfamide, carboplatin and etoposide chemotherapy protocol in relapsed refractory germ cell tumors
  由: Musa Barış Aykan, et al.
  出版: (2022-09-01)
• Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
  由: Mehmet Akce, et al.
  出版: (2016-01-01)
• Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
  由: Ahmed Mahdy, et al.
  出版: (2023-06-01)
• Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
  由: Matthew Mei, et al.
  出版: (2025-05-01)